Biotechnology company developing antibody therapeutics for cancer and autoimmune diseases.
Compass Therapeutics, Inc., a biopharmaceutical company focused on oncology, is actively developing antibody-based therapies for the treatment of various human diseases. At the forefront of its clinical pipeline is CTX-009, an investigational bispecific antibody designed to block Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways. These pathways play crucial roles in angiogenesis and tumor vascularization. Additionally, the company's clinical-stage product CTX-471 is an IgG4 monoclonal antibody that acts as an agonist of CD137, a protein involved in immune regulation.
Compass Therapeutics' innovative pipeline also includes CTX-8371, a bispecific inhibitor targeting the PD-1 and PD-L1 pathways. These pathways are pivotal in immune response regulation and are targeted to enhance anti-tumor immune responses. The company combines cutting-edge scientific research with strategic development to advance therapies that address unmet medical needs in oncology and beyond.
Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics, Inc. continues to expand its portfolio of novel therapeutic candidates. The company's approach integrates deep scientific expertise in antibody discovery and development with a commitment to translating innovative research into transformative therapies for patients.
Driven by a mission to pioneer new treatments, Compass Therapeutics aims to make meaningful advancements in the field of oncology, leveraging its robust pipeline and strategic collaborations to propel the development of next-generation therapies.